Cardiac substrate utilization in heart failure: Where is the relevance of SGLT2 inhibition?

J Thorac Cardiovasc Surg. 2022 Sep;164(3):895-899. doi: 10.1016/j.jtcvs.2021.02.092. Epub 2021 Mar 3.

Authors

Pascal Alexander Mann¹, Michael Lehrke²

Affiliations

¹ Department of Internal Medicine I-Cardiology, University Hospital Aachen, Aachen, Germany.
² Department of Internal Medicine I-Cardiology, University Hospital Aachen, Aachen, Germany. Electronic address: mlehrke@ukaachen.de.

PMID: 33812679
DOI: 10.1016/j.jtcvs.2021.02.092

No abstract available

Keywords: SGLT2 inhibition; adrenergic signaling; cardiac substrate metabolism; heart failure; insulin signaling; mTOR signaling.

Publication types

Editorial

MeSH terms

Diabetes Mellitus, Type 2*
Heart
Heart Failure* / drug therapy
Humans
Sodium-Glucose Transporter 2

Substances

Sodium-Glucose Transporter 2